April 2nd 2025
A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.
January 6th 2025
Sanofi and SK bioscience expand collaboration on pneumococcal conjugate vaccines, including a 21-valent candidate for pediatric populations.
October 30th 2024
Your daily dose of the clinical news you may have missed.
October 24th 2024
The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.
September 20th 2024
New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.